DKK1 and Miyoshi myopathy: Preclinical studies using murine models of myeloma have demonstrated that inhibiting DKK-1 with BHQ880 promotes bone formation, reduces the development of osteolytic lesions, and inhibits MM cell proliferation by altering the bone marrow microenvironment.